Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01893320 · ClinicalTrials.gov registry record · Phase 1
Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT01893320: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01893320 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 66 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01893320, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if the combination of vosaroxin and decitabine can help to control AML or MDS. The safety of these drugs will also be studied.
Interventions
- DRUG Decitabine
- DRUG Vosaroxin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2013-07-18 |
| Est. Completion | 2021-01-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01893320
The ClinicalTrials.gov registry entry for NCT01893320 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Decitabine is the first listed.
NCT01893320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01893320 about?
NCT01893320 is a clinical study titled "Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome". The goal of this clinical research study is to learn if the combination of vosaroxin and decitabine can help to control AML or MDS. The safety of these drugs will also be studied.
What is the current status of trial NCT01893320?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2013-07-18. Estimated completion is 2021-01-11.
What interventions are being tested in trial NCT01893320?
The interventions under investigation include: Decitabine (DRUG), Vosaroxin (DRUG).
Who is sponsoring clinical trial NCT01893320?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.